A plain language summary of the CEPHEUS study: D-VRd for newly diagnosed multiple myeloma patients who are not expected to receive a stem cell transplant

The CEPHEUS study evaluated the effectiveness of adding daratumumab to the standard VRd regimen (bortezomib, lenalidomide, and dexamethasone) in newly diagnosed multiple myeloma patients ineligible for transplant. Read more about the complete study findings and clinical implications in this Plain Language Summary of Publication article published in our partner journal Future Oncology.